AFMD Affimed NV

USD 5.25 0.00 0
Icon

Affimed NV (AFMD) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Buy

Average Analyst
Rating
stockTargetAdvisor

Buy

Top Analyst
Rating
stockTargetAdvisor

Very Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 5.25

0.00 (0.00)%

USD 0.08B

0.03M

USD 7.50(+42.86%)

N/A

Icon

AFMD

Affimed NV (USD)
COMMON STOCK | NSD
USD 5.25
0.00 0
Take a Tour
stockTargetAdvisor

Buy

Average Analyst
Rating
stockTargetAdvisor

Buy

Top Analyst
Rating
stockTargetAdvisor

Very Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.08B

N/A

USD 5.25

Affimed NV (AFMD) Stock Forecast

Show ratings and price targets of :
USD 7.50
(+42.86%)

Based on the Affimed NV stock forecast from 2 analysts, the average analyst target price for Affimed NV is USD 7.50 over the next 12 months. Affimed NV’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Affimed NV is Very Bearish, which is based on 0 positive signals and 6 negative signals. At the last closing, Affimed NV’s stock price was USD 5.25. Affimed NV’s stock price has changed by +0.00% over the past week, +3.55% over the past month and -45.71% over the last year.

No recent analyst target price found for Affimed NV
No recent average analyst rating found for Affimed NV

Company Overview Affimed NV

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase...Read More

https://www.affimed.com

Technologiepark, Heidelberg, Germany, 69120

76

December

USD

USA

Adjusted Closing Price for Affimed NV (AFMD)

Loading...

Unadjusted Closing Price for Affimed NV (AFMD)

Loading...

Share Trading Volume for Affimed NV Shares

Loading...

Compare Performance of Affimed NV Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for AFMD

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Affimed NV (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc 0.00 (0.00%) USD109.10B 27.47 20.00

ETFs Containing AFMD

Symbol Name AFMD's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Affimed NV (AFMD) Stock

Based on ratings from 2 analysts Affimed NV's stock is Buy . Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 1 buy, sell and 1 hold ratings.

Unfortunately we do not have enough data on AFMD's stock to indicate if its a good dividend stock.

Based on targets from 2 analysts, the average taret price for AFMD is USD 7.50 over the next 12 months. The maximum analyst target price is USD 10 while the minimum anlayst target price is USD 5.

Unfortunately we do not have enough data on AFMD's stock to indicate if its overvalued.

The last closing price of AFMD's stock was USD 5.25.

The most recent market capitalization for AFMD is USD 0.08B.

Based on targets from 2 analysts, the average taret price for AFMD is projected at USD 7.50 over the next 12 months. This means that AFMD's stock price may go up by +42.86% over the next 12 months.

We can't find any ETFs which contains Affimed NV's stock.

As per our most recent records Affimed NV has 76 Employees.

Affimed NV's registered address is Technologiepark, Heidelberg, Germany, 69120. You can get more information about it from Affimed NV's website at https://www.affimed.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...